Abstract Purpose: To determine the conformation as well as imine double bond configuration of the antiCandida oximino ester, 3-(1H-imidazol-1-yl)-1-phenyl-propan-1-one O-3-chlorobenzoyl oxime.
INTRODUCTION
The increased incidence of fungal infections in the last half-century has raised this class of infections one of the most current common distress. Invasive nosocomial and systemic fungal infections tare among the main causes of morbidity and mortality, especially in patients with compromised immune systems such as cancer or AIDS, steroid treatments and in organ transplant cases [1] [2] [3] . Candida species appear to be the main causative agent for nosocomial fungal infections with Candida albicans being the cause of the majority of invasive candidiases with about 30 -40 % of mortality [4] .
Azole antifungal agents bearing either imidazole or 1, 2, 4-triazole moieties constitute the major group of the currently available anti-Candida agents [5, 6] . The titled compound 4 is an azolecontaining anti-Candida agent having the imidazole pharmacophore moiety.
There is no previous research pertaining to explore the configuration of the anti-Candida oxime ester 4. Therefore, x-ray crystallography, as a doubtless analytical tool, was used to determine the configuration of the imine double bond of the titled compound 4 as well as its conformation.
EXPERIMENTAL General
Melting points were determined on a Gallenkamp melting point apparatus and were uncorrected. NMR spectra were obtained from a Bruker NMR spectrometer operating at 500 
Preparation of 3-(1H-imidazol-1-yl)-1-phenylpropan-1-one (2)
A mixture containing acetophenone (2.4 g, 20 mmol), paraformaldehyde (0.81 g, 9 mmol), dimethylamine hydrochloride (2.2 g, 27 mmol) and catalytic amount of concentrated hydrochloric acid (0.1 mL) was heated to reflux for two hours in absolute ethanol (5 mL). The reaction mixture was cooled to ambient temperature and acetone (20 mL) was added to precipitate the Mannich base hydrochloride 1. Imidazole (2.4 g, 34.8 mmol) was added to a solution of compound 1 (3.7 g, 17.4 mmol) in water (10 mL) and the reaction mixture was heated at reflux temperature for five hours. The reaction mixture was cooled and the precipitated solid was filtered off to furnish compound 2 (2.7 g, 77%) mp 368-370 K [7] which was used in the next step without any further purification.
Preparation of (1E)-N-hydroxy-3-(1H-imidazol-1-yl)-1-phenylpropan-1-imine (3)
The ketone 2 (2.00 g, 10 mmol), hydroxylamine hydrochloride (1.39 g, 20 mmol), and KOH (1.12 g, 20 mmol) in ethanol (10 mL) were refluxed under stirring for 18 h. The reaction mixture was cooled to room temperature and the insoluble materials were filtered off. The filtrate was concentrated under vacuum and the residue was poured onto ice-cold water (15 mL). The precipitated solid was filtered, dried, and recrystallized from ethanol to give 1.51 g (70 %) of the oxime 3 as colourless crystals mp 428 -430 K [8] .
Preparation of (E)-3-(1H-imidazol-1-yl)-1-phenylpropan-1-one O-3-chloro-benzoyl oxime (4)
A solution of the 3-chlorobenzoic acid (1.1 g, 7 mmol), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDCI.HCl, 1.40 g, 7.3 mmol) and 4-dimethylaminopyridine (DMAP, 400 mg) in dichloromethane (75 mL) was stirred at ambient temperature. The oxime 3 (1.49 g, 6.9 mmol) was added and the reaction mixture was further stirred for 18 h at ambient temperature. The reaction mixture was washed successively with water (2 x 20 mL), 10 % NaHCO 3 solution (2 x 15 mL), and water (2 x 15 mL). The organic layer was separated, dried (Na 2 SO 4 ), evaporated under reduced pressure and the residue was recrystallized (isopropanol) to give 1.51 g (61 %) of 4 as colourless crystals melting point of 383-385 K [8] .
Evaluation of anti-Candida activity
The MIC values of fluconazole and/or compound 4 were determined with a microdilution test (M27-A2 Protocol), according to the reference method of the CLSI [9] . Aliquots of the previously prepared Candida inocula (100 μL) were added to each well of the 96-well microdilution plates; each well contained 100 µL of twofold serial dilutions of fluconazole or compound 4 (1 μg/mL to 500 μg/mL) in RPMI 1640 medium. The plates were incubated at 35 °C for 48 h and the observed turbidity of each well was measured at 490 nm with a microplate ELISA reader. The MICs for fluconazole and/or compound 4 were determined with 80 % growth inhibition at the end point relative to the turbidity of the growth control.
RESULTS

Synthesised compounds
The target compound 4 was synthesized as depicted in Scheme 1. The ketone 2 was obtained from acetophenone via Mannich reaction and subsequent substitution of the produced Mannich base hydrochloride 1 with imidazole to give the pivotal ketone 2. Compound 2 was allowed to react with hydroxylamine hydrochloride in the presence of potassium hydroxide to give the oxime 3. Esterification of the hydroxyl functionality of compound 3 with 3-chlorobenzoic acid was successfully achieved using EDCI. HCl and DMAP to yield the target compound 4. 
3-(1H-
Crystal structure of the titled compound 4
A single crystal of dimensions, 0.58 mm X 0.39 mm X 0.21 mm, was selected for x-ray diffraction analysis. Data were collected on a Bruker APEX-II CCD area diffractometer equipped with graphite monochromatic CuK\a radiation (λ = 1.54178 Å) at 296 (2) K. Cell refinement and data reduction were done by Bruker SAINT [10] . SHELXS-97 [11] was used to solve and refine the titled structure. The final refinement was conducted by full-matrix least-squares techniques with anisotropic thermal data for nonhydrogen atoms on F2 [12] . All the hydrogen atoms were placed in calculated positions and constrained to ride on their parent atoms [12] . Multi-scan absorption correction was applied by the use of SADABS software [10] . The crystallographic data and refinement information are listed in Table 1 . The selected bond lengths and bond angles are summarized in Table 2 . The labelled displacement ellipsoid plot of this molecule is shown in Figure 1 in which minor disordered component has been omitted for clarity. Figure 2 depicts the packing of the molecules in the crystal structure. 
DISCUSSION
The target compound 4 displayed potential in vitro anti-Candida activity and it has been examined using clinical isolates of C. albicans and C. tropicalis. These clinical isolates were practically considered resistant to the gold standard antifungal drug, fluconazole (MIC ˃ 1.6325 µmol/mL). The test compound 4 exhibited MIC values of 0.0221 and 0.7069 µmol/mL being about 74 and two folds more potent than fluconazole against C. albicans and C. tropicalis, respectively [8] .
X-ray crystallography is a crucial analytical tool which can confirm the configuration of the titled oxime ester 4. Accordingly, the assigned (E)-configuration of the titled compound 4 was established via its single crystal x-ray structure. The crystal structure of the titled compound contains one molecule in the asymmetric unit. The imidazole ring and ethyl side chain are statistically disordered over two conformations with a site-occupancy ratio of 0.785 (6): 0.215 (5). Similarity, (SAME) restraint was used for the major and minor components of the disordered imidazole ring and ethyl side chain (C8-C9-N2-C10-C11-N3-C12). The phenyl ring (C1-C6) forms dihedral angles of 1.54 (3)° with the major component of 3-chloro-benzene ring (C14-C19).
The phenyl ring (C1-C6) also forms dihedral angles of 27.00° and 15.86(2)° with the major and minor components of the imidazole ring (N2-C10-C11-N3-C13) respectively. The crystal structure is stabilized by C-H…O non-classical hydrogen bonds along the c axis, where the length between C2-H2A is 0.93 Å and between H2A•••O2 is 2.51 Å and the angle between C2-H2A•••O2 is 138.00° with symmetry code: −x+1, −y+1, −z+2.
CONCLUSION
Single-crystal x-ray structure of the anti-Candida agent, namely (E)-3-(1H-imidazol-1-yl)-1-phenylpropan-1-one O-3-chlorobenzoyl oxime (4) is reported. The assigned (E)-configuration of the title compound 4 is confirmed via its doubtlessly single-crystal x-ray structure. The oxime ester 4 could be considered as an imidazole-bearing new anti-Candida lead prodrug.
